Randomized Controlled Trial
Copyright ©The Author(s) 2022.
World J Clin Cases. Jun 26, 2022; 10(18): 6069-6081
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6069
Figure 1
Figure 1 Study design. DP: Docetaxel/cisplatin; EGFR: Epithelial growth factor receptor; PD: Progressive disease; PP: Pemetrexed/cisplatin; PR: Partial response; SD: Stable disease.